1. Medtech Insight
  2. >>Digital Technologies

Lux Capital’s Deena Shakir Bullish On Women’s Health: ‘Fundamentally A Massive Market Opportunity’

On Shakir’s radar are innovations in AI-powered IVF, robotic cryo-storage solutions, menopause care, home cancer screening and hormone tracking, among other emerging technologies.

 
• By Marion Webb

Medtech Insight talked with Lux Capital’s general partner Deena Shakir about her investments in women’s health, untapped opportunities and barriers, gender equality in investment, and her outlook for investment in women’s health.

Deena Shakir, Lux Capital general partner
• Source: Lux Capital

Women make 80% of health care spending decisions in the US, and investors are beginning to wake up to the growing opportunity in digital and device innovations to support women’s health throughout life’s journey.

Deena Shakir, general partner at Lux Capital, a multi-stage venture capital fund that does investments from pre-seed to pre-initial

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

Synchron And Apple Team Up To Use ‘Mind-Thought Connection’ To Control iPhones, iPads

 
• By Marion Webb

Apple and Synchron are teaming up to develop technologies that will one day allow people who can’t use their hands or voice to control iPhones, iPads and other Apple devices by using only their thoughts.

Ketryx Wants Its Validated AI Agents To Accelerate Compliance Workflows

 
• By Shubham Singh

While the initial focus is medical devices and life sciences, Ketryx sees future opportunities in other high-regulation sectors including automotive, aerospace and defense, pharma manufacturing and nuclear systems.

Axoft Starts Commercializing Soft BCI-Enabling Materials For R&D Use, Aims To Rewrite BCI Playbook

 
• By Marion Webb

After publishing encouraging results from first-in-human trials of its brain-computer interface, Axoft announced plans to sell its BCI-enabling material Fleuron to researchers and private organizations for R&D use. The company sees this as a revenue stream and feedback loop to refine its BCI platform designed for safer, longer-lasting brain implants.

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 
• By Natasha Barrow

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

More from Conferences

Medtronic Presents Data To Boost Hugo’s Odds Of Getting FDA Nod

 
• By Brian Bossetta

Medtronic says results from a recent study on the Hugo robotic-assisted surgery system substantiate its safety and effectiveness for various urological procedures. The company also announced it has submitted the system to the FDA for approval for a urological indication.

HRS Released Framework For Afib Center Of Excellence To Improve Outcomes Through Multidisciplinary Care

 
• By Marion Webb

Medtech Insight sat down with Jared Bunch, chair of AF Center of Excellence Task Force, at HRS 2025 to discuss the newly HRS released framework for Afib Center of Excellence and get his perspective on the role industry could play to help clinicians improve patient outcomes.

Former FDA Head Tells Heart Society To ‘Get Involved’ To Protect Health Innovation

 
• By Elizabeth Orr

Former FDA Commissioner Robert Califf urged the Heart Rhythm Society to engage actively amid federal funding cuts. He highlighted collaboration among researchers, advocates for healthcare integration, and the importance of addressing social determinants of health, while discussing lobbying strategies and the challenges faced by medtech companies.